ReviewJournal of the American Heart Association2023
State of Shock: Contemporary Vasopressor and Inotrope Use in Cardiogenic Shock.
Review in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- The quantitative haemodynamic effect of levosimendan, dobutamine, and milrinone in heart failure patients: a meta-analysis.ESC heart failure · 2026Pooled it
- Prognostic value of baseline glucose levels for mortality in patients with cardiogenic shock: a systematic review and meta-analysis.Journal of cardiothoracic surgery · 2025Pooled it
- IMPELLA COMPARED TO VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION IN CARDIOGENIC SHOCK: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROPENSITY SCORE-MATCHED STUDIES.Shock (Augusta, Ga.) · 2025Pooled it
- Pharmacological assessment of drugs retained in the 1Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Variation in Vasoactive Treatment Selection for Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network (CCCTN).Circulation. Heart failure · 2026Article
- Istaroxime in Acute Heart Failure and Early Cardiogenic Shock: A Calcium-Cycling Approach to Inotropic Therapy.International journal of molecular sciences · 2026Review
- Cardiogenic shock is not a single entity: therapeutic implications.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Cardiogenic Shock: Clinical Management, Outcomes and Future Directions.Journal of cardiovascular development and disease · 2026Review
- Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis and Cardiogenic Shock.Circulation reports · 2026Article
- Phenylephrine per se or Combined with Pregabalin Ameliorates Mononeuropathic Pain in Rats.Pharmaceutics · 2026Article
- Successful use of methylene blue following out of hospital cardiac arrest: a case report.European heart journal. Case reports · 2026Article
- Contemporary evidence to inform management of deceased potential thoracic organ donors after brain death.JHLT open · 2026Article
- Impact of Early versus Delayed Vasopressin Initiation on 28-Day Mortality in Older Adults with Septic Shock.Therapeutics and clinical risk management · 2026Article
- Experts' recommendations for the management of adult patients with cardiogenic shock.Annals of intensive care · 2026Article
- Vasoactive-Inotropic Score Reduction Rate Is Highly Associated With Prognosis for Critically Ill Patients With Cardiogenic Shock: Insights From the Real-World Dynamic Data.Cardiovascular therapeutics · 2026Observational
- Comparative Efficacy of Noradrenaline vs. Other Vasopressors on Outcomes in Patients With Cardiogenic Shock - A Systematic Review and Meta-Analysis.Circulation reports · 2025Article
- Myocarditis-Associated Cardiogenic Shock: A Nationwide Multicenter Study.Journal of the American Heart Association · 2025Article
- Troponin predicts mortality in heart failure-related cardiogenic shock.Internal and emergency medicine · 2025Article
- Contemporary Practice Patterns of Vasoactive Use in Cardiogenic Shock in the American Heart Association Cardiogenic Shock Registry.Journal of the American Heart Association · 2025Article
- Association Between Vasoactive Inotropic Score and Clinical Outcomes in Patients With Fulminant Myocarditis.Korean circulation journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiogenic shock is characterized by tissue hypoxia caused by circulatory failure arising from inadequate cardiac output. In addition to treating the pathologic process causing impaired cardiac function, prompt hemodynamic support is essential to reduce the risk of developing multiorgan dysfunction and to preserve cellular metabolism. Pharmacologic therapy with the use of vasopressors and inotropes is a key component of this treatment strategy, improving perfusion by increasing cardiac output, altering systemic vascular resistance, or both, while allowing time and hemodynamic stability to treat the underlying disease process implicated in the development of cardiogenic shock. Despite the use of mechanical circulatory support recently garnering significant interest, pharmacologic hemodynamic support remains a cornerstone of cardiogenic shock management, with over 90% of patients receiving at least 1 vasoactive agent. This review aims to describe the pharmacology and hemodynamic effects of current pharmacotherapies and provide a practical approach to their use, while highlighting important future research directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.